Goserelin vs Leuprolide
How they differ
- FDA status, the same for both (FDA-approved). Goserelin: FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis.1,2 Leuprolide: FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products.3,4,5,6,7,8
- Kinds of studies cited. Goserelin: large randomized human trials. Leuprolide: limited human data. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Goserelin | Leuprolide |
|---|---|---|
| What it is | A synthetic decapeptide analogue of GnRH that, with continued use, suppresses the pituitary’s release of reproductive hormones, according to the label.1 | A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.3 |
| FDA status | FDA-approved FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis1,2 FDA-approved. Drugs@FDA lists Zoladex with an original approval date of December 29, 1989. The cited label has no boxed warning.1,2 | FDA-approved FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products3,4,5,6,7,8 FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.3,4,6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.9 | Not among the six peptides the policy lists.9 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 30 ClinicalTrials.gov records and 30 PubMed records collected | 117 ClinicalTrials.gov records and 48 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗
Drugs@FDA via openFDA · Official source · Source checked November 15, 2026
- 9HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 10Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026